Skip to main content

Anzalone Christopher Richard's Form 4 filing

Arrowhead Pharmaceuticals, Inc. (ARWR) · filed Mar 5, 2025

Accession no.
0001628280-25-010672
Filed
Mar 5, 2025
Trade date
Mar 3-4, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $5.27M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Anzalone Christopher RichardCIK 0001423029Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 3, 2025Common StockMOption exerciseAcquired+166,667$7.75+$1,291,669.253,940,469Direct
Mar 4, 2025Common StockMOption exerciseAcquired+133,333$7.75+$1,033,330.754,073,802Direct
Mar 3, 2025Common StockSSaleDisposed−166,667$18.03−$3,005,006.013,907,135Direct
Mar 4, 2025Common StockSSaleDisposed−133,333$17.02−$2,269,327.663,773,802Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 3, 2025Common StockMOption exerciseDisposed−166,667$0.00$0185,059Direct
Mar 3, 2025Common StockMOption exerciseDisposed−133,333$0.00$051,726Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)